Content area

|
|

Amyloid transthyretinkardiomyopati

Forfatter(e)
Peter Riis Hansen1, 2 & Martin Krakauer3

1) Hjertemedicinsk Afdeling, Herlev-Gentofte Hospital 2) Institut for Klinisk Medicin, det Sundhedsvidenskabelige Fakultet, Københavns Universitet 3) Afdelingen for Nuklearmedicin, Herlev-Gentofte Hospital

 

Ugeskr Læger 2020;182:V11190627

Reference: 
Ugeskr Læger 2020;182:V11190627
Blad nummer: 

Peter Riis Hansen & Martin Krakauer:

Transthyretin amyloid cardiomyopathy

Ugeskr Læger 2020;182:V11190627

Transthyretin amyloid cardiomyopathy (ATTR-CM) resulting from deposition of transthyretin amyloid fibrils in the heart is an underrecognised cause of heart failure in the elderly and is associated with a poor life expectancy. The diagnosis can now be made by radionuclide imaging with bone tracers, provided absence of plasma-cell dyscrasia. Recent evidence has suggested a considerable prevalence of ATTR-CM, and effective treatment has become available. This review summarises these new developments, which have ushered a new era in the detection and clinical management of ATTR-CM.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Niels Rud Haagensen | 25/09
10 kommentarer
af John Vitger | 25/09
3 kommentarer
af Simon Bahn Glerup | 24/09
7 kommentarer
af Peter Matzen | 21/09
1 Kommentar
af Finn Vallø Hansen | 21/09
1 Kommentar
af Johan Ludvig Reventlow | 19/09
2 kommentarer
af Andreas Gothardt Lundh | 17/09
1 Kommentar
af Bjørn Søeberg | 17/09
33 kommentarer